Quick Answer
Inhibitor Therapeutics, Inc. reported Net Income of -$3.30 million for fiscal year 2025.
Inhibitor Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$3.30M | +1.2% |
| 2024 | -$3.34M | -10.3% |
| 2023 | -$3.03M | -125.0% |
| 2022 | $12.11M | +4153.9% |
| 2021 | -$298.6K | +71.8% |
| 2020 | -$1.06M | +61.3% |
| 2019 | -$2.73M | +39.9% |
| 2018 | -$4.55M | +10.8% |
| 2017 | -$5.10M | +27.1% |
| 2016 | -$7.00M | -77.2% |
| 2015 | -$3.95M | +0.6% |
| 2014 | -$3.98M | -116.6% |
| 2013 | -$1.84M | -1084.7% |
| 2012 | $186.4K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$712.2K | +2.6% | -7.9% |
| June 30, 2025 | -$659.9K | -31.5% | -4.3% |
| March 31, 2025 | -$632.8K | +7.6% | +13.4% |
| September 30, 2024 | -$731.0K | -10.0% | -45.7% |
| June 30, 2024 | -$501.7K | +23.4% | +26.7% |
| March 31, 2024 | -$684.7K | -26.9% | -3.0% |
| September 30, 2023 | -$664.8K | -755.6% | -1.6% |
| June 30, 2023 | -$654.5K | -743.8% | -21.3% |
- Inhibitor Therapeutics, Inc. showed an increase of +1.2% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Inhibitor Therapeutics, Inc.’s net income has declined by 1870.9% (from $186.4 thousand to -$3.30 million).
- The most recent figure is from Inhibitor Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: